Regulus Therapeutics Inc. financial data

Symbol
RGLS on Nasdaq
Industry
Pharmaceutical Preparations
Location
4224 Campus Point Court, Suite 210, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.24K % +196%
Debt-to-equity 9.25 % -73.7%
Return On Equity -53.1 % +43.7%
Return On Assets -48.6 % +30.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 65.5M shares +224%
Common Stock, Shares, Outstanding 65.5M shares +224%
Entity Public Float 27.4M USD -5.52%
Common Stock, Value, Issued 66K USD +230%
Weighted Average Number of Shares Outstanding, Basic 65.5M shares +234%
Weighted Average Number of Shares Outstanding, Diluted 65.5M shares +234%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 31.5M USD +56.5%
General and Administrative Expense 13.1M USD +36.3%
Operating Income (Loss) -44.6M USD -49.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -41.6M USD -44.7%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -41.6M USD -44.7%
Earnings Per Share, Basic 2.1 USD/shares -1.41%
Earnings Per Share, Diluted 2.1 USD/shares -1.41%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 26.4M USD +2.09%
Cash, Cash Equivalents, and Short-term Investments 87.3M USD +183%
Other Assets, Current 1.09M USD -11.5%
Assets, Current 91.7M USD +161%
Property, Plant and Equipment, Net 1.02M USD +1.49%
Operating Lease, Right-of-Use Asset 1.03M USD -36.6%
Intangible Assets, Net (Excluding Goodwill) 25K USD -30.6%
Other Assets, Noncurrent 21K USD
Assets 93.8M USD +148%
Accounts Payable, Current 792K USD +32.2%
Employee-related Liabilities, Current 2.45M USD +14.7%
Accrued Liabilities, Current 1.11M USD +78.5%
Liabilities, Current 6.48M USD -21.4%
Operating Lease, Liability, Noncurrent 476K USD -61.6%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 6.96M USD -26.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax 120K USD
Retained Earnings (Accumulated Deficit) -547M USD -8.24%
Stockholders' Equity Attributable to Parent 86.8M USD +207%
Liabilities and Equity 93.8M USD +148%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -8.74M USD -7.74%
Net Cash Provided by (Used in) Financing Activities 93.1M USD
Net Cash Provided by (Used in) Investing Activities -78.5M USD -624%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 65.5M shares +224%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 5.82M USD -4.29%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 26.4M USD +2.09%
Interest Paid, Excluding Capitalized Interest, Operating Activities 45K USD -69.6%
Deferred Tax Assets, Valuation Allowance 140M USD +6.11%
Deferred Tax Assets, Gross 141M USD +5.96%
Operating Lease, Liability 1.24M USD -36%
Payments to Acquire Property, Plant, and Equipment 229K USD +22800%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -41.5M USD -44.5%
Lessee, Operating Lease, Liability, to be Paid 1.3M USD -37.9%
Property, Plant and Equipment, Gross 5.31M USD +7.08%
Operating Lease, Liability, Current 764K USD +9.77%
Lessee, Operating Lease, Liability, to be Paid, Year Two 277K USD -66.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 824K USD +3%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 63K USD -60.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 277K USD -66.4%
Deferred Tax Assets, Operating Loss Carryforwards 92.6M USD +2.8%
Unrecognized Tax Benefits 6.25M USD +8.04%
Lessee, Operating Lease, Liability, to be Paid, Year Four 0 USD -100%
Depreciation, Depletion and Amortization 81K USD +68.8%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 6.31M USD +192%
Interest Expense 500K USD -30.4%